Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Breast Cancer Metastasis Depends on Expression of Leader Cell Protein

By BiotechDaily International staff writers
Posted on 24 Dec 2013
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Cell biologists have identified a protein that they regard as a potential drug target in a unique class of breast cancer cells that lead the process of metastasis into surrounding tissues.

Carcinomas typically migrate into normal tissues as a cohesive multicellular unit, a process termed collective invasion. It has been unclear how different subpopulations of cancer cells contributed to this process.

Investigators at Johns Hopkins University (Baltimore, MD, USA) developed three-dimensional organoid assays to identify the most invasive cancer cells in primary breast tumors. They reported in the December 12, 2013, online edition of the journal Cell that collective invasion was led by specialized cancer cells (leader cells) that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, examination of human tumor samples showed that K14-expressing cells led collective invasion in the major human breast cancer subtypes.

To confirm the role of K14 in the invasive process, the investigators used gene therapy techniques to block its expression in some tumor lines. Cancer cells with blocked K14 expression and similar but untreated cancer cells were then implanted into different sites on the same mouse. Examination of the resulting tumors showed that leader cells were present in the K14-expressing tumors and were leading vigorous invasions into normal tissue. In the tumors with blocked K14 expression essentially no invasions occurred.

"Metastasis is what most threatens breast cancer patients, and we have found a way to stop the first part of the process in mice," said senior author Dr. Andrew Ewald, assistant professor of cell biology at Johns Hopkins University. "We are still several years away from being able to use these insights to help patients with breast cancer, but we now know which tumor cells are the most dangerous, and we know some of the proteins they rely on to do their dirty work. Just a few leader cells are sufficient to start the process of metastasis, and they require K14 to lead the invasion."

Related Links:

Johns Hopkins University



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.